

High efficacy with deep nurse-administered propofol sedation for advanced gastroenterologic endoscopic procedures

Authors

Jeppe Thue Jensen¹, Pernille Hornslet¹, Lars Konge², Ann Merete Møller³, Peter Vilmann¹

Institutions

¹ Gastro unit D, Department of endoscopy, Copenhagen University Hospital Herlev, Denmark

² Copenhagen Academy for Medical Education and Simulation, University of Copenhagen and the Capital Region of Denmark, Denmark

³ Department of Anaesthesiology, Copenhagen University Hospital Herlev, Denmark

Bibliography

DOI <http://dx.doi.org/10.1055/s-0041-107899>
Published online: 7.12.2015
Endoscopy International Open 2016; 04: E107–E111
© Georg Thieme Verlag KG
Stuttgart · New York
E-ISSN 2196-9736

Corresponding author

Jeppe Thue Jensen

Gastro unit D
Department of Endoscopy
University Hospital Herlev,
Gastroenheden D, Endoskopi
Herlev Ringvej 75 | 1735 Herlev
Jeppe.thue.jensen.01@regionh.dk

Background and study aims: Whereas data on moderate nurse-administered propofol sedation (NAPS) efficacy and safety for standard endoscopy is abundant, few reports on the use of deep sedation by endoscopy nurses during advanced endoscopy, such as Endoscopic Retrograde Cholangiopancreatography (ERCP) and Endoscopic Ultrasound (EUS) are available and potential benefits or hazards remain unclear. The aims of this study were to investigate the efficacy of intermittent deep sedation with propofol for a large cohort of advanced endoscopies and to provide data on the safety.

Patients and methods: All available data from patients sedated with intermittent deep NAPS for ERCP, EUS or double balloon enteroscopy (DBE), since the method was implemented in May 2007 through December 2012 were included for evaluation in a retrospective case-control design.

Results: Data from 1899 patients undergoing 1899 procedures were included for evaluation. All but one procedure were completed with intermittent deep NAPS. The mean propofol dose was 397 mg (SD: 232.4) and the infusion rate was 23.9 mg/kg. The frequency of hypoxia was 4.3% and 20 patients needed assisted ventilation (1.1%). Anesthesiologic support was requested eight times (0.4%). One patient was intubated due to suspected aspiration.

Conclusions: Intermittent deep NAPS for advanced endoscopies in selected patients provided an almost 100% success rate. However, the rate of hypoxia, hypotension and respiratory support was high compared with previously published data, but the method was still assessed as safe.

Introduction

Nurse-administered propofol sedation (NAPS) or non-anesthesiologist-administered propofol (NAAP) sedation is increasingly used for procedural sedation, particularly gastrointestinal endoscopy. Previously published large volume studies primarily evaluated the use of moderate NAPS for gastroscopies, sigmoidoscopies, and colonoscopies [1,2]. Evidence on NAPS efficacy and safety for advanced interventional endoscopy, such as endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic ultrasound (EUS), is more limited [3,4] and even more so when deep sedation is applied.

The increased focus on patient related quality and the development of advanced endoscopies such as ERCP, EUS, enteroscopies, and advanced colonoscopies has led to increased sedation requirements. The procedures are often longer than standard endoscopy and require a high degree of patient compliance in order to be successful [5].

Hence, either sedation or general anesthesia is almost always needed. The use of conscious sedation is sometimes insufficient during advanced endoscopy, especially upper endoscopy, and the use of deep sedation by non-anesthesia staff is debatable, particularly in the presence of considerable comorbidity [6,7]. Therefore, general anesthesia is commonly applied. The use of intermittent deep sedation could lead to a larger proportion of successfully completed advanced endoscopies without the need for general anesthesia. Administration by non-anesthesia staff would reduce the procedure costs and sedation would shorten time to induction, time to discharge, and put less stress on the vital functions of the patient than general anesthesia. Deep sedation with midazolam, alone or in combination with an opioid is impractical. In a high-output unit, the prolonged discharge time after deep sedation is often unacceptable and the risk of re-sedation after antidote administration is increased. Furthermore, the

License terms



clinical effect of midazolam has a high degree of interpersonal variation [8].

With a short, context-sensitive half-life of 2 to 4 minutes, propofol administration can provide for periods of deep sedation with no risk of re-sedation and fast readiness for discharge [9]. With the increased sedation requirements, adverse events occur more frequently during advanced endoscopy [3,4] than during standard endoscopy [10,12] and likely even more so during deep sedation. From a safety perspective, adverse events should be minor and self-resolving or successfully handled by the endoscopy team without health consequences for the patient and the efficacy should be high to render deep sedation beneficial as compared to conscious sedation or general anesthesia. The aims of this study were to analyze the efficacy and safety of intermittent deep sedation with propofol in a large cohort of advanced endoscopies.

Patients and methods

Ethical approval was obtained from the Capital Region Ethics Committee No: H-4-2013-171 and the National Data protection agency No: HEH-2013-077. We used a retrospective case-control design, with cases being patients who developed an adverse event (dichotomous as 0 or 1) and the remainder serving as controls. All available data from patients sedated with NAPS for ERCP, EUS or double balloon enteroscopy (DBE) since the method was implemented in May 2007 through December 2012 were included for evaluation.

Patients

According to our guidelines, inclusion criteria for NAPS were age \geq 16 years and ability to comply with 6 hours of fasting from solids and 2 hours of fasting from fluids. Patients were excluded if they were American Society of Anesthesiologists (ASA) class >2 (ASA class 3 patients in a stable condition were allowed); had a body mass index >35 kg/m²; were allergic to soy, eggs, or peanuts; or had a history of complicated anaesthesia, potentially difficult airway (composite score of Mallampati score, atlanto-occipital movement, thyromental distance and dental status), ventricular retention, pregnancy, or sleep apnea. All patients undergoing emergency endoscopies were excluded.

Training

We have used a refract bolus propofol regimen in our unit since 2007. The guideline concept was originally developed by J. A. Walker (Medford, Oregon) and adapted to Danish standards. The endoscopist and nurse administering propofol complete 2½-day theoretical and practical course with full-scale simulation training in administration and the handling of adverse events. The course is completed with an exam and followed by bedside observation and supervised sedation (1 day for doctors, 4 weeks for nurses), gradually working more independently.

Sedation

Depth of sedation was assessed prior to introduction of the endoscope based on normal tone verbal stimulation, loss of ciliary reflexes, and loss of muscle tone. During the procedure, the depth and frequency of respiration served as the most important indicator of sedation depth. The sedation depth aimed for was a sleeping, unresponsive, and motionless patient with no gagging or coughing during introduction of the endoscope. This state

was maintained throughout procedure, corresponding to deep sedation during endoscopic stimulation and moderate or deep sedation in the absence of stimulation. If a patient's cardiopulmonary status was unstable, as expressed by a depression in vital parameters, the sedation was lifted one level.

Propofol administration

Propofol was administered as intermittent bolus monotherapy by a dedicated endoscopy nurse, using the same guidelines as for standard endoscopies. Sufficient sedation for gag-free introduction of the endoscope was achieved with a dose of 100 mg minus the patient's age in years, but no more than 60 mg (hence, an 80-year-old would receive 20 mg). Additional doses of half the initial dose could be administered every 45–60 seconds until the patient was unresponsive to verbal and light tactile stimulation, as assessed by the team together. Maintenance of sedation was achieved with intermittent doses of 10–20 mg if the patient showed signs of discomfort, sound or movement, or every 1 to 2 minutes if the patient was a sleep with stable cardiopulmonary status. The dedicated nurse continuously monitored the patient's vital parameters on the monitor and the depth and frequency of respiration by assessing movement of the thorax and the air flow over the nose and mouth in the palm of a hand.

Adverse events

All patients were monitored with pulse oximetry, blood pressure (BP) taken every five minutes, and electrocardiography. Saline infusion (500 mL/hr) and supplemental oxygen (3 L/min) flow on a nasal cannula were administered to all patients and initiated a minimum of 3 minutes prior to sedation. Adverse events were oxygen saturation (SAT%) $<92\%$, measured with pulse oximetry or a drop in BP from baseline of more than 50 mmHg systolic or 30% in mean arterial pressure (MAP). Furthermore, arrhythmia was registered. In near adverse events, temporary increases in saline infusion to 2 L/h and oxygen flow to 5 L/min were administered as a precaution. Handling of adverse events was recorded as a dichotomous outcome (0 or 1) in case of administration of ephedrine 5–10 mg, airway manipulation (oral- or nasal airway and suction) and mask ventilation.

Data items and statistical analysis

Sedation was considered efficient when the procedure was completed, regardless of findings. Sedation was considered inefficient when the procedure was incomplete or disrupted due to pain, movement or a sedation-related adverse event. Other than adverse events and handling, baseline demographics recorded were recorded sex, age, ASA class, procedure type, duration of sedation (available for the last 1200 procedures), and total propofol dose. Unsuccessful procedures and procedures that required anesthesiologic assistance also were recorded.

Statistics were computed using IBM SPSS™ version 19. Binary logistic regression was used to compare demographic risk factors and propofol administration in cases and controls. A *P* value <0.05 was considered significant.

Results

Data from 1899 patients undergoing 1899 procedures were included for evaluation. All but one procedure were completed with intermittent deep NAPS. One ERCP was disrupted and anesthesiologic expertise was summoned (0.05% of total). The mean

Table 1 Patient and procedure characteristics.

	EUS, ERCP, DBE
Patients, n	1899
Age, n	1896
Mean (SD)	62.5 (15.7)
Range (years)	15–96
Sex, n	1899
M (%)	824 (43.4)
F (%)	1075 (56.6)
ASA class, n	1882
I (%)	455 (24.0)
II (%)	1158 (61.0)
III (%)	269 (14.2)
Unknown (%)	17 (0.9)
Total procedures	1899
EUS (%)	1401 (73.8)
ERCP (%)	455 (24.0)
DBE (%)	43 (2.3)
Sedation	
Propofol dose, n	1819
Mean (SD)	397.0 mg (232.4)
Median	340 mg
Sedation time, n	1194
Mean (SD)	27.9 min (30.9)
Median	21.0 min
Mg propofol/min, n	1193
Mean (SD)	23.9 mg/min (25.8)
Median	16.5 mg/min
Adverse events	
Hypoxia <92% SAT	81 (4.3)
Hypotension	107 (5.6)
Handling	
Assisted ventilation	20 (1.1)
Airway manipulation	86 (4.5)
Efedrin	24 (1.3)
Anesthesiologic assistance	8 (0.4)

N, patients with available data; SD, standard deviation; EUS, endoscopic ultrasound; ERCP, endoscopic retrograde cholangiopancreatography; DBE, double balloon enteroscopy

total propofol dose administered was 397 mg with a mean infusion rate of 23.9 mg/min and the median procedure duration was 21 minutes. The rate of hypoxia was 4.5% with 20 patients needing assisted ventilation (1.1%) and the rate of hypotension was 5.6%, as shown in **Table 1**. Anesthesiologic support was requested for 8 patients, 7 of whom were stabilized by the endoscopy team before the anesthesiologist arrived. The eight patient was intubated due to suspected aspiration after puncture of a pancreatic pseudocyst that contained 3L of fluid. As shown in **Table 2**, the only demographic and procedure-related predictors of adverse events were age ($P < 0.001$) and total propofol dose ($P = 0.007$).

Discussion

The use of intermittent deep sedation provided a procedure success rate of nearly 100% in 1899 patients compliant with our NAPs criteria. However, intermittent deep sedation requires a relatively high propofol dose and leads to a higher frequency of sedation-related respiratory adverse events as compared with historical data, whereas the circulatory events rate seems less affected. Age and total propofol dose, but not ASA class, were associated with a higher frequency of adverse events.

The target state of motionless, unalert, and unaware were achieved for the full duration of all procedures and allowed for 99.95% of the procedures to be completed successfully, so the efficacy of sedation was good. The level of sedation was only registered prior to the procedure and before admission to the recovery room, but to avoid gagging, movement or cough, deep sedation is necessary for at least some part of EUS, DBE and ERCP and definitely achievable with a mean infusion rate of 23.9 mg/min propofol, hence the term “intermittent deep sedation.” In a previously published study [13] of patients undergoing standard endoscopic procedures (sigmoidoscopy, colonoscopy, and esophago-gastroduodenoscopy) who were sedated with the same regimen by the same nurses, the average propofol consumption was 331.6 mg and the infusion rate 20.9 mg/min, both significantly lower than that required for advanced endoscopy. The higher propofol consumption during ERCP and EUS is confirmed by a number of authors reporting on mean propofol consumption between 78 mg and 277 mg during colonoscopy [9] as compared with 106–388 mg (Outlier low 51 mg and high 519 mg) (397 mg in the current study) for an advanced endoscopic population [3] or studies targeting deep sedation during endoscopy [6, 7, 14–18]. Adding to the higher propofol dose, the patients were older and more were ASA class 3 as compared with patients undergoing standard endoscopy, and therefore likely to be more responsive to propofol [13, 19, 20].

The screening of patients suited for intermittent deep sedation serves different purposes. A higher ASA classification and age are known to affect dose-response and assessment is necessary in order to adjust the propofol dose accordingly and thereby avoid an unpredictable course of sedation in patients with a possible reduced compensatory capacity [19, 20]. As described in a previous study [21], airway management during advanced upper endoscopy, particularly ERCP but probably also EUS, is still a matter of discussion. Depending on culture and local setup, in-hospital patients are often intubated or sedated by anesthesia personnel and out-of-hospital patients are increasingly sedated by gastroenterologists. In this study, only fasting patients were included and only non-obese ($BMI \leq 35$) patients with a low comorbidity (ASA 1, 2, or stable class 3) were offered propofol. Causal analysis of the disrupted ERCP due to possible aspiration subsequently resulted in a review of the guideline so that pseudocyst drainage of a certain size required endotracheal intubation. The patient did not develop hypoxia or pneumonia. Furthermore, propofol was not given if patients presented a potentially difficult airway or difficult mask ventilation (DMV). Whereas the difficult airway is an exclusion criteria, screening for DMV is informally performed according to the OBESE criteria: Overweight ($BMI \geq 26 \text{ kg/m}^2$), Beard, Edentulous, Snoring, Elderly (age older than 55 years) [22]. Although not necessarily excluded, patients at risk are observed closely and preferably examined in the lateral recumbent position to avoid obstruction of airways. In a previous study [22], the incidence of DMV was 5% in a mixed population. Utilizing an airway screening strategy in this study, the percentage was evidently lower, and no DMV has been encountered. The theoretical risk of DMV could possibly be reduced even further if the “OBESE” guideline was used as an exclusion criterion. To conclude on procedure safety, the incidence and severity of adverse events, the handling capability and the consequence should be assessed simultaneously. With this guideline, treatment is initiated before SAT% declines below 92%. Only three patients experienced concomitant SAT% < 88% and hypotension, all transient with a duration < 30 seconds and resolved with airway

Table 2 Adverse events.

	No hypoxia	Hypoxia, n (%)	P value ¹	No hypotension	Hypotension (%)	P value ¹	Overall P value ²
Patients, n	1818	81 (4.5)		1792	107 (5.6)		
Age, n	1815	81	0.057	1789	107	0.001	<0.001
Mean (SD)	62.3 (15.8)	66.4 (11.9)		62.2 (15.8)	68.4 (13.0)		
Sex							
M, n	742	42 (5.1)	0.078	2543	98 (3.7)	0.674	0.639
F, n	1036	39 (3.6)		4093	106 (2.5)		
ASA Class							
I, n	441	14 (3.1)	0.492	2078	35 (1.7)	0.809	0.826
II, n	1101	57 (4.9)		4169	135 (3.1)		
III, n	259	10 (3.7)		360	32 (8.2)		
Procedure total, n	1818	81 (4.5)		1792	107 (5.6)		
EUS, n	1336	65 (4.6)	0.379	1319	82 (5.9)	0.263	0.141
ERCP, n	439	16 (3.5)		435	20 (4.4)		
DBE, n	43	0 (0)		38	5 (11.6)		
Sedation							
Propofol dose, n	1742	77	0.445	1735	84	0.009	0.007
Mean (SD)	397.1 (231.5)	394.5 (252.6)		394.7 (231.0)	443.1 (255.8)		
Sedation time, n	1147	47	0.935	1162	32	0.194	0.410
Mean (SD)	27.8 (31.0)	30.9 (28.3)		27.2 (31.2)	27.2 (18.1)		
Mg/min, n	1146	47	0.265	1162	31	0.085	0.145
Mean (SD)	24.1 (26.2)	17.0 (11.1)		23.8 (26.0)	27.6 (20.0)		

n, patients with available data; SD, standard deviation.

¹ Logistic regression P values

² Logistic regression P values for hypoxia and hypotension combined

manipulation, increased oxygen and saline flow. None of these individuals required mask ventilation and no adverse event resulted in intubation or arrhythmia. In addition, all patients were expected to have some compensatory capacity. Mask ventilation were used in 20 cases to resolve hypoventilation regardless of saturation, and the frequency was significantly higher than during standard endoscopy (0.6%) [13], aiming for the same depth of sedation, and higher than in all but one (1.8%) of the previously reported studies on advanced endoscopy (0–0.9%) [23]. The offensive mask ventilation strategy used in our unit could explain some of this difference. The threshold for anesthesiologic assistance was low and help was called as soon as anyone in the team felt uncertain about the course of events. Hence, seven of the calls were preventive and not yet associated with a serious adverse event, but the possible development of one.

Administering deep propofol sedation as refract bolus therapy is laborious due to the frequent administration (every 1–2 min) and costly due to the extra nurse or physician required to administer propofol and monitor the patient. Recent research suggests that target-controlled infusion (TCI) could be a hands-free alternative to refract bolus administration. One study on deep sedation during standard endoscopy reported a frequency of hypoxia of 0% and a frequency of hypotension of 12% [18]. However, only 32% of patients were motionless during the entire procedure and 22% was reported to have moved severely. Movement can be acceptable, or even beneficial during colonoscopy repositioning, but less so during interventional endoscopy. One randomized controlled study of TCI for EUS reported good success with almost the same propofol dose as the current study and a low frequency of hypoxia (3%) and no cases of assisted ventilation [24]. Manually controlled infusion (MCI) has also been suggested as a hands-free solution for advanced endoscopy and provides decent working conditions with a low rate of hypoxia <90% (1%) [25] or good working conditions and similar rates of hypoxia (8%) but a higher

rate of hypotension (14%) and prolonged recovery in the perfusor group vs. the refract bolus therapy group [14]. The refract bolus regimen used in this study was implemented due to the high degree of attention achieved with a dedicated nurse reassessing the patient before every bolus. Furthermore, endoscopy, particularly advanced endoscopy, is a dynamic process with passages requiring higher doses to maintain a motionless patient. Bolus therapy allows for a quick adaptation to these changes. It is, however, possible that TCI of propofol can provide for sedation deep enough to avoid infusion adjustments, as argued by one author [24].

This study has some limitations. The retrospective design increases the risk of selection bias and information bias. Furthermore, actual measurement of sedation depth in intervals would have been valuable. However, the tactile stimulation required to arouse a deeply sedated patient can be disturbing and arousal of a sleeping moderately sedated patient also seems unnecessary and therefore is not performed routinely. Furthermore, assessing sedation depth is subjective and interobserver-dependent and, therefore, prone to bias. The strength of this study is the large sample of advanced endoscopies, particularly EUS, which is why we believe that intermittent deep NAPS administered by trained personnel is highly useful and applicable for this cohort

Conclusions



Intermittent deep NAPS for advanced endoscopic procedures in selected patients provided an almost 100% success rate, no patient discomfort, and required higher doses of propofol than previously reported, but was still safe. However, the rate of hypoxia and hypotension was high. Higher age and total propofol dose were predictors of adverse events.

Competing interests: Funding from Arvid Nilssons Fond

References

- 1 Frieling T, Heise J, Kreysel C et al. Sedation-associated complications in endoscopy—prospective multicentre survey of 191142 patients. *Z Gastroenterol* 2013; 51: 568–572
- 2 Rex DK, Deenadayalu VP, Eid E et al. Endoscopist-directed administration of propofol: a worldwide safety experience. *Gastroenterology* 2009; 137: 1229–1237
- 3 Goudra BG, Singh PM, Gouda G et al. Safety of non-anesthesia provider-administered propofol (NAAP) sedation in advanced gastrointestinal endoscopic procedures: comparative meta-analysis of pooled results. *Dig Dis Sci* 03. 03 2015: [Epub ahead of print]
- 4 Cheriyan DG, Byrne MF. Propofol use in endoscopic retrograde cholangiopancreatography and endoscopic ultrasound. *World J Gastroenterol* 2014; 18: 5171–5176
- 5 Ootaki C, Stevens T, Vargo J et al. Does general anesthesia increase the diagnostic yield of endoscopic ultrasound-guided fine needle aspiration of pancreatic masses? *Anesthesiology* 2012; 117: 1044–1050
- 6 Nayar DS, Guthrie WG, Goodman A et al. Comparison of propofol deep sedation versus moderate sedation during endoscopy. *Dig Dis Sci* 2010; 55: 2537–2544
- 7 Yarmus LB, Akulian JA, Gilbert C et al. Comparison of moderate versus deep sedation for endobronchial ultrasound transbronchial needle aspiration. *Ann Am Thorac Soc* 2013; 10: 121–126
- 8 Horn E, Nesbit SA. Pharmacology and pharmacokinetics of sedatives and analgesics. *Gastrointest Endosc Clin N Am* 2004; 14: 247–268
- 9 Dewitt J, McGreevy K, Sherman S et al. Nurse-administered propofol sedation compared with midazolam and meperidine for EUS: a prospective, randomized trial. *Gastrointest Endosc* 2008; 68: 499–509
- 10 Singh H, Poluha W, Cheang M et al. Propofol for sedation during colonoscopy (Review). *Cochrane Database Syst Rev* 2008; 4
- 11 Rex DK, Heuss LT, Walker JA et al. Trained registered nurses/endoscopy teams can administer propofol safely for endoscopy. *Gastroenterology* 2005; 129: 1384–1391
- 12 Kulling D, Orlandi M, Inauen W. Propofol sedation during endoscopic procedures: how much staff and monitoring are necessary? *Gastrointest Endosc* 2007; 66: 443–449
- 13 Jensen JT, Moeller AM, Hornslet P et al. Moderate and deep nurse-administered propofol sedation is safe. *Dan Med J* 2015; 62: A5049 [Epub ahead of print]
- 14 Riphaus A, Geist C, Schrader K et al. Intermittent manually controlled versus continuous infusion of propofol for deep sedation during interventional endoscopy: a prospective randomized trial. *Scand J Gastroenterol* 2012; 47: 1078–1085
- 15 Amorniyotin S, Leelakusolvong S, Chalayonnawin W et al. Age-dependent safety analysis of propofol-based deep sedation for ERCP and EUS procedures at an endoscopy training center in a developing country. *Clin Exp Gastroenterol* 2012; 5: 123–128
- 16 Chun SY, Kim KO, Park DS et al. Safety and efficacy of deep sedation with propofol alone or combined with midazolam administered by nonanesthesiologist for gastric endoscopic submucosal dissection. *Gut Liver* 2012; 6: 464–470
- 17 Lera Dos Santos ME, Maluf-Filho F, Chaves DM et al. Deep sedation during gastrointestinal endoscopy: propofol-fentanyl and midazolam-fentanyl regimens. *World J Gastroenterol* 2013; 19: 3439–3446
- 18 Chan WH, Chang SL, Lin CS et al. Target-controlled infusion of propofol versus intermittent bolus of a sedative cocktail regimen in deep sedation for gastrointestinal endoscopy: Comparison of cardiovascular and respiratory parameters. *J Dig Dis* 2014; 15: 18–26
- 19 Scheepstra GL, Booij LH, Rutten CL et al. Propofol for induction and maintenance of anaesthesia: comparison between younger and older patients. *Br J Anaesth* 1989; 62: 54–60
- 20 Coley S, Mobley KA, Bone ME et al. Haemodynamic changes after induction of anaesthesia and tracheal intubation following propofol or thio-pentone in patients of ASA grade I and III. *Br J Anaesth* 1989; 63: 423–428
- 21 Goudra B, Singh PM. ERCP: The Unresolved Question of Endotracheal Intubation. *Dig Dis Sci* 2014; 59: 513–519
- 22 Langeron O, Masso E, Huraux C et al. Prediction of difficult mask ventilation. *Anesthesiology* 2000; 92: 1229–1236
- 23 Pagano N, Arosio M, Romeo F et al. Balanced Propofol Sedation in Patients Undergoing EUS-FNA: A Pilot Study to Assess Feasibility and Safety. *Diagn Ther Endosc* 2011: DOI 10.1155/2011/542159
- 24 Fanti L, Agostoni M, Arcidiacono PG et al. Target-controlled infusion during monitored anesthesia care in patients undergoing EUS: Propofol alone versus midazolam plus propofol A prospective double-blind randomised controlled trial. *Digest Liver Dis* 2007; 39: 81–86
- 25 Yusoff IF, Raymond G, Sahai AV. Endoscopist administered propofol for upper-GI EUS is safe and effective: a prospective study in 500 patients. *Gastrointest Endosc* 2004; 60: 356–360